Clinical Trials Logo

Unresectable Solid Neoplasm clinical trials

View clinical trials related to Unresectable Solid Neoplasm.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04250597 Terminated - Solid Tumor Clinical Trials

Study of GNX102 in Patients With Advanced Solid Tumors

Start date: July 29, 2020
Phase: Phase 1
Study type: Interventional

GNX102 is a humanized monoclonal antibody (mAb), an engineered biotechnology product, developed by GlycoNex that targets certain cancer cells by binding with high affinity to specific structures on cancer cells. Specifically, GNX102 binds to novel glycan structures caused by glycosylation changes in tumors. Patients with epithelial origin cancers that have a likelihood of GNX102 targeted antigen expression based on previous studies, including colorectal, hepatocellular, non-small cell lung, gastric, breast, pancreatic, cutaneous, acral, or mucosal melanoma, esophageal, prostate, and epithelial uterine cancers, can be screened for enrollment in the study.

NCT ID: NCT03366103 Terminated - Clinical trials for Metastatic Malignant Solid Neoplasm

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

Start date: March 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the best dose and side effects of navitoclax and how well it works when given together with vistusertib in treating patients with small cell lung cancer and solid tumors that have come back (relapsed). Drugs used in chemotherapy, such as navitoclax, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vistusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving navitoclax and vistusertib may work better than navitoclax alone in treating patients with small cell lung cancer and solid tumors.